CRP and COVID-19: Although intravenous thrombolysis is not contraindicated in patients with COVID-19, leukocytosis, an elevated C-reactive protein level, and an elevated D-dimer level are risk factors for hemorrhagic transformation, as well as for post-thrombolysis mortality(30,31).